European Union suspends GVK Biosciences' generic drugs

Published: 3-Aug-2015
Regulatory Pharmaceutical

Indian company found to be manipulating data


European Union countries have until 20 August to suspend the sale of 700 generic drugs made by Indian company GVK Biosciences (GVK Bio), after the firm was found to be manipulating data, the European Commission said.

The firm was hired by drug companies to test whether the impact of generic versions of drugs was equal to the original, but investigations last year showed irregularities in all nine trials inspected.

The European Medicines Agency (EMA) said the problems, 'which stretched back years, highlight critical deficiencies in the quality system in place' at the company.

Specifically, GVK Bio had been manipulating electrocardiograms (ECGs) at its site in Hyderabad, according to Francois Herbert, Deputy Head of France’s National Agency for Medicines and Health Products Safety (ANSM), which carried out the inspections.

But the Commission said there is no reason to believe the drugs, including common pain reliever ibuprofen, had caused any health issues. A few have been re-authorised based on data from other labs.

The EMA recommended suspension in May this year, but several European countries, including France, Germany, Belgium and Luxembourg, had already begun blocking sales as early as December 2014.

  • Companies:
  • European Commission
  • GVK Biosciences Private Limited
See more

You may also like

Regulatory

Timber Pharmaceuticals receives EC orphan drug designation

Read more
TMB-001 is a topical isotretinoin, formulated using the company’s patented IPEG delivery system

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  5. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

Timber Pharmaceuticals receives EC orphan drug designation

TMB-001 is a topical isotretinoin, formulated using the company’s patented IPEG delivery system
Regulatory

European Commission purchases additional Moderna vaccine doses

Under the terms of the agreement, the European Commission has the option to purchase an additional 150 million doses to be delivered in 2022
Regulatory

Tagrisso receives full approval in the EU

For patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer
Regulatory

Medicine and food authorities strongly recommend re-think of antimicrobials use in livestock

EMA and EFSA give joint opinion on EU measures to reduce antimicrobials use in food-producing animals
Ingredients

Pharma industry says EDC criteria need a risk-based approach

Strict, science-based guidelines will be implemented as soon as possible
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

EU considers endocrine disrupter controls

It has long been known that pharmaceutical residues can become hormone-affecting ‘endocrine disrupters’ when released into the environment and future controls are likely – but how will the legislators tackle the issue? Manufacturing Chemist reports
Regulatory

European Commission, EMA and WHO step up co-operation to protect global public health

New working arrangement will allow timely sharing of non-public information
Subscribe now